Genomics in CKD: Is This the Path Forward?

Advances in Chronic Kidney Disease

Volumn 23, Issue 2, 2016, Pages 120-124

  Nadkarni, Girish N ^a   Horowitz, Carol R ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CKD; Disparities; Genetics; Genomics; Pharmacogenomics

Indexed keywords

ANTIHYPERTENSIVE AGENT; IMMUNOSUPPRESSIVE AGENT; APOL1 PROTEIN, HUMAN; APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN;

ANCESTRY GROUP; APOL1 GERNE; BIOTECHNOLOGY; CHRONIC KIDNEY DISEASE; DISEASE COURSE; END STAGE RENAL DISEASE; GENE; GENE SEQUENCE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOMICS; GENOTYPE; HERITABILITY; HUMAN; HYPERTENSION; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NEPHROLOGY; PHARMACOGENOMICS; POPULATION GENETICS; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; TREATMENT RESPONSE; CHRONIC KIDNEY FAILURE; ETHNOLOGY; GENETICS; PHARMACOGENETICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSLATIONAL RESEARCH;

APOLIPOPROTEINS; GENOMICS; HUMANS; LIPOPROTEINS, HDL; NEPHROLOGY; PHARMACOGENETICS; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84959881230     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2016.01.017     Document Type: Review

References (64)

1. Grams M.E., Chow E.K.H., Segev D.L., Coresh J. Lifetime incidence of CKD stages 3-5 in the United States. Am J Kidney Dis 2013, 62(2):245-252.
2. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108(17):2154-2169.
3. Fried L.F., Katz R., Sarnak M.J., et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 2005, 16(12):3728-3735.
4. Levey A.S., Coresh J. Chronic kidney disease. Lancet 2012, 379(9811):165-180.
5. Nicholas S.B., Kalantar-Zadeh K., Norris K.C. Racial disparities in kidney disease outcomes. Semin Nephrol 2013, 33(5):409-415.
6. Crews D.C., Pfaff T., Powe N.R. Socioeconomic factors and racial disparities in kidney disease outcomes. Semin Nephrol 2013, 33(5):468-475.
7. 2015 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States 2015, United States Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, Available at:, Accessed January 2, 1016. http://www.usrds.org/adr.aspx.
8. Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Stamler J. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997, 277(16):1293-1298.
9. O'Seaghdha C.M., Fox C.S. Genome-wide association studies of chronic kidney disease: what have we learned?. Nat Rev Nephrol 2012, 8(2):89-99.
10. Satko S.G., Sedor J.R., Iyengar S.K., Freedman B.I. Familial clustering of chronic kidney disease. Semin Dial 2007, 20(3):229-236.
11. Gorski M., Tin A., Garnaas M., et al. Genome-wide association study of kidney function decline in individuals of European descent. Kidney Int 2015, 87(5):1017-1029.
12. Köttgen A., Pattaro C., Böger C.A., et al. New loci associated with kidney function and chronic kidney disease. Nat Genet 2010, 42(5):376-384.
13. O'Seaghdha C.M., Fox C.S. Genome-wide association studies of chronic kidney disease: what have we learned?. Nat Rev Nephrol 2012, 8(2):89-99.
14. Liu C.T., Garnaas M.K., Tin A., et al. Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. PLoS Genet 2011, 7(9):e1002264.
15. Kao W.H.L., Klag M.J., Meoni L.A., et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008, 40(10):1185-1192.
16. Kopp J.B., Smith M.W., Nelson G.W., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40(10):1175-1184.
17. Genovese G., Friedman D.J., Ross M.D., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329(5993):841-845.
18. Lipkowitz M.S., Freedman B.I., Langefeld C.D., et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013, 83(1):114-120.
19. Kopp J.B., Nelson G.W., Sampath K., et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011, 22(11):2129-2137.
20. Thomson R., Genovese G., Canon C., et al. Evolution of the primate trypanolytic factor APOL1. Proc Natl Acad Sci U S A 2014, 111(20):E2130-E2139.
21. Tzur S., Rosset S., Shemer R., et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010, 128(3):345-350.
22. Rosset S., Tzur S., Behar D.M., Wasser W.G., Skorecki K. The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus. Nat Rev Nephrol 2011, 7(6):313-326.
23. Freedman B.I., Pastan S.O., Israni A.K., et al. APOL1 genotype and kidney transplantation outcomes from deceased African American donors. Transplantation 2016, 100(1):194-202.
24. Riella L.V., Sheridan A.M. Testing for high-risk APOL1 alleles in potential living kidney donors. Am J Kidney Dis 2015, 66(3):396-401.
25. Ito K., Bick A.G., Flannick J., et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res. 2014, 114(5):845-850. 10.1161/CIRCRESAHA.114.302347.
26. Mukamal K.J., Tremaglio J., Friedman D.J., et al. APOL1 Genotype, Kidney and Cardiovascular Disease, and Death in Older Adults. Arterioscler Thromb Vasc Biol December 2015, 10.1161/ATVBAHA.115.305970.
27. Grams M.E., Matsushita K., Sang Y., et al. Explaining the racial difference in AKI incidence. J Am Soc Nephrol 2014, 25(8):1834-1841.
28. Chawla L.S., Kimmel P.L. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 2012, 82(5):516-524.
29. Hsu C.Y., Lin F., Vittinghoff E., Shlipak M.G. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003, 14(11):2902-2907.
30. Johns T.S., Estrella M.M., Crews D.C., et al. Neighborhood socioeconomic status, race, and mortality in young adult dialysis patients. J Am Soc Nephrol 2014, 25(11):2649-2657.
31. Norris K.C., Agodoa L.Y. Unraveling the racial disparities associated with kidney disease. Kidney Int 2005, 68(3):914-924.
32. Peralta C.A., Katz R., DeBoer I., et al. Racial and ethnic differences in kidney function decline among persons without chronic kidney disease. J Am Soc Nephrol 2011, 22(7):1327-1334.
33. Powe N.R. To have and have not: health and health care disparities in chronic kidney disease. Kidney Int 2003, 64(2):763-772.
34. Appel L.J., Wright J.T., Greene T., et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010, 363(10):918-929.
35. Ruggenenti P., Cravedi P., Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010, 6(6):319-330.
36. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345(12):861-869.
37. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329(20):1456-1462.
38. Brewster L.M., van Montfrans G.A., Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004, 141(8):614-627.
39. Gard P.R. Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot review. Int J Mol Epidemiol Genet 2010, 1(2):145-157.
40. Santos P.C.J.L., Krieger J.E., Pereira A.C. Renin-angiotensin system, hypertension, and chronic kidney disease: pharmacogenetic implications. J Pharmacol Sci 2012, 120(2):77-88.
41. Ueda S., Meredith P.A., Morton J.J., Connell J.M., Elliott H.L. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation 1998, 98(20):2148-2153.
42. Jacobsen P., Rossing K., Rossing P., et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998, 53(4):1002-1006.
43. Parving H.H., de Zeeuw D., Cooper M.E., et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 2008, 19(4):771-779.
44. Narayanan M., Pankewycz O., Shihab F., Wiland A., McCague K., Chan L. Long-term outcomes in African American kidney transplant recipients under contemporary immunosuppression: a four-yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study. Clin Transpl 2014, 28(2):184-191.
45. Beermann K.J., Ellis M.J., Sudan D.L., Harris M.T. Tacrolimus dose requirements in African-American and Caucasian kidney transplant recipients on mycophenolate and prednisone. Clin Transpl 2014, 28(7):762-767.
46. Narayanan M., Pankewycz O., El-Ghoroury M., et al. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. Transplantation 2013, 95(4):566-572.
47. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002, 54(10):1271-1294.
48. Gaber A.O., Alloway R.R., Bodziak K., Kaplan B., Bunnapradist S. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation 2013, 96(2):191-197.
49. Gordon E.J., Ladner D.P., Caicedo J.C., Franklin J. Disparities in kidney transplant outcomes: a review. Semin Nephrol 2010, 30(1):81-89.
50. Taber D.J., Douglass K., Srinivas T., et al. Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients. Am J Nephrol 2014, 40(1):19-28.
51. Inrig J.K., Califf R.M., Tasneem A., et al. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis 2014, 63(5):771-780.
52. Konstantinidis I., Nadkarni G.N., Yacoub R., et al. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Intern Med 2016, 176(1):121-124.
53. Welch B.M., Kawamoto K. The need for clinical decision support integrated with the electronic health record for the clinical application of whole genome sequencing information. J Pers Med 2013, 3(4):306-325.
54. Overby C.L., Erwin A.L., Abul-Husn N.S., et al. Physician attitudes toward adopting genome-guided prescribing through clinical decision support. J Pers Med 2014, 4(1):35-49.
55. Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC) 2016, Available at:, Accessed January 2, 1016. http://www.genome.gov/27554614.
56. Gottesman O., Kuivaniemi H., Tromp G., et al. The electronic medical records and genomics (eMERGE) network: past, present, and future. Genet Med 2013, 15(10):761-771.
57. Implementing Genomics in Practice (IGNITE) 2016, Available at:, Accessed January 2, 1016. http://www.genome.gov/27554264.
58. Sanderson S.C., Suckiel S.A., Zweig M., Bottinger E.P., Jabs E.W., Richardson L.D. Development and preliminary evaluation of an online educational video about whole-genome sequencing for research participants, patients, and the general public. Genet Med 2015, Accessed February 4, 2016. 10.1038/gim.2015.118.
59. Osheroff J.A., Teich J.M., Middleton B., Steen E.B., Wright A., Detmer D.E. A roadmap for national action on clinical decision support. J Am Med Inform Assoc 2007, 14(2):141-145.
60. Kawamoto K., Houlihan C.A., Balas E.A., Lobach D.F. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ 2005, 330(7494):765.
61. Weitzel K.W., Alexander M., Bernhardt B.A., et al. The IGNITE network: a model for genomic medicine implementation and research. BMC Med Genomics 2016, 9(1):1.
62. Horowitz C.R., Abul-Husn N.S., Ellis S., et al. Determining the effects and challenges of incorporating genetic testing into primary care management of hypertensive patients with African ancestry. Contemp Clin Trials 2015, 47:101-108.
63. Gottesman O., Scott S.A., Ellis S.B., et al. The CLIPMERGE PGx Program: clinical implementation of personalized medicine through electronic health records and genomics-pharmacogenomics. Clin Pharmacol Ther 2013, 94(2):214-217.
64. Lohmann K., Klein C. Next generation sequencing and the future of genetic diagnosis. Neurotherapeutics 2014, 11(4):699-707.